A Study to Compare Efficacy in Terms of Plasma Human Immunodeficiency Virus-Type 1 (HIV-1) Ribonucleic Acid (RNA) Between 2 Fixed Dose Combinations After a Switch in Fully Suppressed Patients (SALIF)
This study is not yet open for participant recruitment.
Verified April 2013 by Janssen-Cilag International NV
Sponsor:
Janssen-Cilag International NV
Information provided by (Responsible Party):
Janssen-Cilag International NV
ClinicalTrials.gov Identifier:
NCT01709084
First received: October 16, 2012
Last updated: April 5, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is not yet open for participant recruitment. |
|---|---|
| Estimated Study Completion Date: | August 2015 |
| Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |